In that vein, it has been shown that genetic or pharmacologic blockade of a key pathway responsible for suppressing inflammation, the transforming growth factor-beta (TGF-β)-Smad 2/3 signaling cascade, reduces AD-like pathology. Here, TGFB1 is linked to Alzheimer disease.